Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 86, Issue 3, 2007, Pages 261-268

  Takamatsu, Yasushi ^a   Sasaki, Noriaki ^a   Eto, Tetsuya ^b   Nagafuji, Koji ^c   Abe, Yasunobu ^c   Choi, Ilseung ^d   Ogata, Kentaro ^a   Hara, Shuuji ^a   Suzumiya, Junji ^a   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b HAMANOMACHI HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Busulfan; Conditioning; Dose adjustment; Hematopoietic stem cell transplantation; Pharmacokinetics

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; LEVOFLOXACIN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; EWING SARCOMA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PROSPECTIVE STUDY; RECIPIENT; RELIABILITY;

ADMINISTRATION, ORAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BUSULFAN; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JAPAN; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; STOMATITIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 36048947430     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.07013     Document Type: Article

References (25)

1. Hassan M, Ljungman R Bolme R et al. Busulfan bioavailability. Blood. 1994;84:2144-2150.
2. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
3. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055-3060.
4. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000;25:925-930.
5. McCune JS, Gibbs JR Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155-165.
6. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201-1207.
7. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102:31-35.
8. Takamatsu Y, Ogata K, Yamauchi K, et al. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Jpn J Clin Oncol. 2005;35:400-403.
9. Hara S, Tsuchie M, Tsujioka R, et al. High-performance liquid chromatographic quantification of busulfan in human serum after fluorescence derivatization by 2-naphthalenethiol. Anal Sci. 2000;16:287-291.
10. Sandstrom M, Karlsson MO, Ljungman R et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulfan in' bone marrow transplantation recipients. Bone Marrow Transplant. 2001;28:657-664.
11. Higuchi S, Aoyama T, Horioka M. PEDA: a microcomputer program for parameter estimation and dosage adjustment in clinical practice. J Pharmacobiodyn. 1987;10:703-718.
12. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
13. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987:778-783.
14. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:167-173.
15. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.
16. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33:181-186.
17. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res. 1996;16:2083-2088.
18. Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman R Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:429-435.
19. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820-826.
20. Hansen JA, Petersdorf EW. Unrelated donor hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Malden, Mass: Blackwell Science; 1999:915-928.
21. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:1013-1018.
22. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001;29:264-267.
23. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574-1577.
24. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis. 1995;16:1243-1245.
25. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:345-351.